Revolution Medicines Begins Phase 3 Trial for Daraxonrasib in First-Line Metastatic Pancreatic Cancer
Summary
Revolution Medicines has commenced treating patients in its global Phase 3 RASolute 303 clinical trial for daraxonrasib. This pivotal trial evaluates daraxonrasib as a monotherapy and in combination with chemotherapy for previously untreated metastatic pancreatic ductal adenocarcinoma (PDAC), a highly aggressive cancer with significant unmet medical need. The initiation of a Phase 3 trial is a critical milestone for the company's lead RAS(ON) inhibitor program, advancing a key pipeline asset towards potential regulatory approval. Success in this registrational trial could materially impact the company's future revenue and market position in oncology. Investors will now monitor updates on patient enrollment and anticipate future data readouts from this and other ongoing daraxonrasib Phase 3 trials.
At the time of this announcement, RVMD was trading at $96.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $19.5B. The 52-week trading range was $29.17 to $124.49. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.